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Summary 
The HERBY trial was a phase-II open-label, randomised, multicentre trial evaluating 
bevacizumab (BEV) in addition to temozolomide/radiotherapy in patients with newly-
diagnosed non-brainstem high-grade glioma (HGG) between the ages of 3-18 years. We 
carried out comprehensive molecular analysis integrated with pathology, radiology and 
immune profiling. In post-hoc subgroup analysis, hypermutator tumours (mismatch repair 
deficiency and somatic POLE/POLD1 mutations) and those biologically resembling 
pleomorphic xanthoastrocytoma (PXA-like, driven by BRAF_V600E or NF1 mutation) had 
significantly more CD8+ tumour-infiltrating lymphocytes, and longer survival with the addition 
of BEV. Histone H3 subgroups (hemispheric G34R/V and midline K27M) had a worse outcome 
and were immune cold. Future clinical trials will need to take into account the diversity 
represented by the term ‘HGG’ in the paediatric population. 
 
 
Significance 
We validate in the prospective clinical trial setting the biological and clinical diversity of 
paediatric high grade glioma previously described in large retrospective series, underpinned 
by detailed pathological and radiological analysis. Although adding bevacizumab (BEV) to 
standard temozolomide/radiotherapy did not improve survival across the whole cohort, we 
identify disease subgroups with MAPK activation to harbour an enhanced CD8+ T cell immune 
response, which may derive benefit from the addition of BEV. If confirmed in another study, 
this would represent the first predictive biomarker for this regimen in these tumours, and points 
the way for new therapeutic strategies for subgroups of children with high grade glioma. 
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Introduction 
High grade gliomas (HGG) in children, like their adult counterparts, continue to have a bleak 
prognosis, with a median overall survival of 9-15 months (Cohen et al., 2011; Jones et al., 
2016; Ostrom et al., 2015). Recent integrated molecular profiling initiatives have shown that 
paediatric HGG are biologically distinct from their adult counterparts, with subgroups of the 
disease marked by recurrent mutations in genes encoding histone H3 variants having different 
age of incidence, anatomical location, clinical outcome, and a range of biological parameters 
(Jones and Baker, 2014; Mackay et al., 2017; Paugh et al., 2010; Schwartzentruber et al., 
2012; Sturm et al., 2012; Wu et al., 2012; Wu et al., 2014). Histone wild-type tumours have 
widely differing mutational burdens, ranging from infant cases (<3 years) driven by single gene 
fusion events through to patients with biallelic mismatch repair deficiency harbouring some of 
the highest mutational rates in human cancer (Jones and Baker, 2014; Mackay et al., 2017; 
Shlien et al., 2015; Wu et al., 2014).  
 
The rapid advances in our understanding of paediatric HGG have come predominantly from 
the accumulation of numerous disparate retrospective collections, a reflection of the rarity of 
the disease. Clinical trial cohorts with ancillary biomarker analyses have been relatively limited 
in their scope, and historically have focussed on single marker analyses. These include the 
Children’s Oncology Group ACNS0126 (radiotherapy (RT) / temozolomide (TMZ))(Cohen et 
al., 2011) and ACNS0423 (RT/TMZ followed by TMZ and lomustine)(Jakacki et al., 2016) 
studies, which report on the frequency and clinical correlations of MGMT expression 
(ACNS0126)(Jakacki et al., 2016; Pollack et al., 2006), IDH1 mutation (ACNS0423)(Pollack 
et al., 2011) as well as phosphorylated Akt expression(Pollack et al., 2010a) and microsatellite 
instability (both)(Pollack et al., 2010b). The CCG-945 study (“8 in 1” chemotherapy)(Finlay et 
al., 1995) first reported on the prognostic significance of p53 expression/mutation (Pollack et 
al., 2002), in addition to the presence/absence of 1p19q co-deletion (Pollack et al., 2003b). 
 
  5 
This latter study also highlighted the critical importance of pathological review in the diagnosis 
of paediatric HGG, and subsequent interpretation of clinical trial results (Gilles et al., 2008; 
Pollack et al., 2003a), particularly in midline locations (Eisenstat et al., 2015). It has 
subsequently become clear that numerous histological subtypes of HGG can harbour distinct 
genetic drivers and have considerably better clinical outcomes, such as BRAF V600E 
mutations in epithelioid glioblastoma (GBM), anaplastic ganglioglioma and anaplastic 
pleomorphic xanthoastrocytoma (PXA) (Hatae et al., 2016); in the latter two categories, this 
overlaps with the lower-grade entities lacking obvious anaplasia. Additional histone wild-type 
cases of otherwise uncontroversial HGG have been found to be biologically and clinically more 
similar to several types of low grade glioma (LGG) and PXA (Korshunov et al., 2015), 
highlighting the importance of an integrated diagnosis combining molecular and histological 
features.  
 
The HERBY trial (study BO25041; clinicaltrials.gov NCT01390948) was a phase II, open-label, 
randomised, multicentre, comparator study of the addition of the anti-angiogenic agent 
bevacizumab (BEV) to radiotherapy (RT) and temozolomide (TMZ) in patients between the 
ages of 3-18 years with newly-diagnosed non-brainstem HGG (Grill et al., 2018). Central 
confirmation of HGG diagnosis was mandatory before randomisation, followed by consensus 
review by five independent expert neuropathologists. Real-time panel radiological assessment 
was also incorporated. An exploratory endpoint of the study was to establish a biospecimen 
repository for correlative molecular profiling. In addition to its role in tumour angiogenesis, 
VEGF restricts immune cell activity, and BEV has been demonstrated to facilitate recruitment 
of T cells to infiltrate tumours (Wallin et al., 2016), as well as increase the ratio of CD8/CD3-
positive T cells in adult glioblastoma specimens (Scholz et al., 2016). We therefore also sought 
to explore the immune profile of cases within the HERBY cohort. Through an integrated 
analysis of biological, clinicopathological, radiological and immunological variables, we 
provide a detailed description of the diversity of the trial cohort, and identify disease subgroups 
with an elevated immune response who benefited from the addition of BEV. 
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Results  
The translational research cohort is representative of the whole clinical trial population 
The total HERBY cohort comprised 121 randomised patients at diagnosis (3-18 years) plus 
three infant cases (<3 years) at relapse. Of these, 113 patients consented to the translational 
research programme (Table S1A). Tumour tissue was collected either from resection (n=93) 
or biopsy (n=20), although 24 cases failed to provide either sufficient quantity or quality of 
sample for molecular analysis. For the remaining 89 cases, material was available in the form 
of either fresh frozen material (FF, n=36), formalin-fixed paraffin embedded pathology 
specimens (FFPE, n=79), or both (n=26). These were subjected to Sanger sequencing for 
H3F3A (n=89), exome sequencing (n=86), Illumina 450k methylation BeadArray profiling 
(n=74), CD8 immunohistochemistry (n=70), MS-PCR for MGMT promoter methylation (n=36), 
a capture-based sequencing panel for common fusion gene detection (n=68), and RNA 
sequencing (n=20) (Figure 1A).  
 
The translational research cohort, representing a subset (91%) of the randomised trial, 
displayed equivalent clinical characteristics to the full dataset, with no difference in the primary 
end-point of 1 year event-free survival (EFS) with the addition of BEV to the standard therapy 
of temozolomide and radiotherapy (median 12.0 versus 8.3 months, p=0.605, log-rank test) 
(Figure 1) (Grill et al., 2018). The cohort contained 66 (58%) hemispheric and 47 (42%) non-
brainstem midline tumours, with the latter location conferring a significantly shorter EFS 
(median 8.0 versus 14.7 months, p=0.00201, log-rank test) (Figure 1C). Histone mutation 
status was a significant predictor of worse prognosis for H3F3A_K27M (24/89, 27%; median 
EFS=7.9 months; p=0.0063, log-rank test) and also trended towards shorter survival for 
H3F3A_G34R/V (7/89, 8%; median EFS=8.3 months; p=0.096, log-rank test) (Figure 1D).  
 
Integrated molecular analysis defines the major (epi)genomic alterations in pHGG 
We used the Heidelberg brain tumour classifier on Illumina 450k methylation array data to 
assign a molecular subgroup to each of 74 samples for which such data was available (Table 
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S1B). After excluding low-scoring assignments (<0.2), we used a simplified system to classify 
tumours as either H3K27M (n=18), H3G34R/V (n=6) or IDH1 (n=4) (integrating gene mutation 
data in low-scoring cases); as resembling pleomorphic xanthoastrocytoma (PXA-like, n=9) or 
other low grade glioma (LGG-like, n=3); and aggregating the remaining tumours (HGG-WT, 
n=34) (Figure 2A). IDH1 tumours represented the oldest patients (median=17.2 years, 
others=11.2, p=0.0107, t-test), with LGG-like representing the youngest category (median=5.7 
years, p=0.0098, t-test) (Figure 2B). These two subgroups each had significantly better 
outcome in terms of EFS (p=0.0281 and p=0.0386, log-rank test), though not overall survival 
(OS, p=0.0935 and p=0.129, log-rank test) (Figure 2C), when compared individually to the 
remaining tumours. The PXA-like showed a trend towards longer OS (p=0.0867, log-rank test) 
compared to the rest. When IDH1, PXA-like and LGG-like tumours were excluded from the 
analysis, the significant differences between histone mutant and HGG-WT groups were 
absent (H3K27M - p=0.257 EFS and p=0.0746 OS; H3G34R/V - p=0.552 EFS and p=0.116 
OS, log-rank test). 12/78 (15%) samples harboured a methylated MGMT promoter, though 
this was largely restricted to the H3G34R/V (n=3, p=0.0249, Fishers exact test) and IDH1 
(n=3, p=0.0062, Fishers exact test) subgroups (Figure 1A), and was not significantly 
associated with survival (Figure 1B) in these uniformly TMZ-treated patients.  
 
We used 450k methylation array and exome sequencing coverage to derive DNA copy 
number profiles for 86 paediatric high grade glioma (pHGG) (Figure S1C). Taken with the 
somatic single nucleotide variants (SNVs) and small insertion/deletions (InDels) from whole 
exome sequencing (Table S1E), and candidate gene fusion events from capture-based panel 
sequencing (n=68) and RNAseq (n=20) (Table S1F), we derived an integrated map of genetic 
alterations across the translational research cohort (Figure 3A). The most common alteration 
was TP53 mutation (39/82, 48%), followed by ATRX deletion/mutation (25/82, 30%), PDGFRA 
amplification/mutation (17/82, 21%) and CDKN2A/B deletion (15/82, 18%). Additional 
recurrent alterations in receptor tyrosine kinases (EGFR, MET, ERBB3, IGF1R, NTRK2), PI3-
kinase/mTOR (PTEN, PIK3CA, TSC2, PIK3R1), and MAP-kinase (NF1, BRAF, PTPN11, 
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PTPN12) pathways were common, as were amplifications/mutations in various genes 
associated with cell cycle regulation (RB1, CDK4, MDM2, CCND2). Taking a minimum variant 
allele frequency of 5% as a threshold, the median number of somatic mutations per sample 
was 15 (range=0-337) (Figure 3B), with the exception of four cases for whom there were more 
than a hundred-fold more, and were excluded from gene-level counts. 
 
Paediatric HGG comprise a diverse set of biological and clinicopathological subgroups 
Two cases were highlighted from the methylation subgrouping as potentially representing non-
HGG entities. One case classifying as CNS neuroblastoma with FOXR2 activation (CNS NB-
FOXR2, methylation classifier score=0.617), was found to have no evidence of FOXR2 
alterations. A further case, a compact and necrotic tumour with perivascular radiating 
arrangements (Figure S2A), displayed a methylation classifier score strongly indicative of a 
high grade neuroepithelial tumour with MN1 alteration (CNS HGNET-MN1, methylation 
classifier score=0.713) (Figure S2B). We identified a novel candidate alteration in this case 
fusing exon 1 of MN1 (22q12.1) to exon 3 of CARD6 (5p13.1) (Figure S2C), and thus appears 
most likely to fall into this categorization.  
 
Three cases classified more closely to either pilocytic astrocytoma (PA, n=2) or desmoplastic 
infantile ganglioglioma (DIG, n=1) by 450k methylation profiling. The first two harboured MAPK 
dysregulation in the form of either BRAF_V600E or intragenic FGFR1 duplication (Figure 
S2C). Histologically, after Pathology Committee re-review, no piloid features were seen, and 
anaplastic features were evident (Figure S2D). The DIG-like case was found in the infant 
cohort (2.7 years). None of these three patients died during the course of follow-up, and 
although numbers are small, were all found in the right frontal and temporo-parietal lobes with 
central predominance (Figure S2E). 
 
There were four cases with IDH1 hotspot mutations (Figure S3A). Three were classified as 
WHO grade III AA, IDH1_R132 positive by IHC, with concurrent TP53 and ATRX mutations. 
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The remaining case was originally classified as a mixed oligo-astrocytoma, which by virtue of 
the presence of IDH1_R132 and TERT promoter mutation (C228T) as well as copy number 
loss of chromosomes 1p and 19q, would be described as an oligodendroglioma according to 
WHO 2016. (Figure S3B). Across the whole cohort, IDH1 mutation conferred a significantly 
longer EFS (p=0.0398, log-rank test), though not OS (p=0.110, log-rank test) (Figure S3C), 
and were restricted to the frontal lobes (Figure S3D). 
 
After excluding IDH1 mutant cases, the remaining H3F3A and BRAF wild-type cases (n=38) 
represented a heterogeneous mix of genomic profiles, with recurrent deletions/mutations in 
the common pHGG tumour suppressor genes TP53 (n=11), ATRX (n=5), CDKN2A/B (n=7), 
NF1 (n=8), RB1 (n=7) and PTEN (n=5), but also with an enrichment of gene amplifications in 
PDGFRA (n=5, with KIT and KDR, n=4), CDK4 (n=7, with MDM2, n=4), EGFR, (n=4),  MET 
(n=2), CCND2 (n=3) and MYCN (n=3) (Figure S4A). The most common methylation subclass 
in these cases was designated ‘GBM_RTK_MYCN’ (n=6), however included only one of those 
with MYCN amplification, and with no other common amplifications or mutations. Seven cases 
harboured none of the recurrently altered genes previously described in pHGG, and clearly 
represent a subgroup which warrants further investigation. Together, these cases had bilateral 
hemispheric distribution with predominant deep right cerebral localization (Figure 4B).  
 
H3F3A mutation confers poor prognosis for both K27M and G34R/V substitutions 
Histone mutations have been shown to be present in approximately half of all pHGG (Mackay 
et al., 2017), with a clear negative impact on survival for K27M (Karremann et al., 2018; 
Khuong-Quang et al., 2012; Mackay et al., 2017), though the situation is less clear for G34R/V 
mutations (Bjerke et al., 2013; Korshunov et al., 2015; Mackay et al., 2017). There were seven 
cases with H3F3A_G34 substitutions (six G34R and one G34V), with 6/7 (86%) cases 
additionally harbouring TP53 and/or ATRX mutations (5/7, 71% both), whilst 5/7 (71%) also 
contained PDGFRA amplification and/or mutation (Figure 4A). There were no other recurrent 
mutations, although isolated instances of mutations in PI3K signalling (PIK3CA, PTEN) and 
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DNA repair (ERCC1) were observed. Histologically, there were four GBM, two anaplastic 
astrocytoma (AA) with multinucleated cells and one HGG, NOS. (Figure 4B). Tumours were 
Olig2 negative (7/7) with strong nuclear accumulation of p53 (6/7). H3F3A_G34R/V mutant 
tumours had a tendency to being diffusely infiltrative with predominant deep left 
temporoparietal involvement (Figure 4C). Across all tumours within this hemispheric 
subgroup, patients harbouring these mutations trended towards a shorter EFS (median=8.3 
months; p=0.0572, log-rank test) and had a significantly shorter OS (median=12.0 months; 
p=0.00765, log-rank test) (Figure 4D), though this association was lost when IDH1, PXA-like 
and LGG-like tumours were excluded (p=0.440 EFS and p=0.139 OS, log-rank test) (Figure 
S5A).  
 
By contrast, K27M substitutions were restricted to midline regions (n=24). 15/21 (71%) exome 
sequenced cases carried additional amplifications/mutations in the RTK-PI3K pathway across 
a range of genes (PDGFRA, MET, IGF1R, FGFR1, PTEN, PIK3CA, PIK3R1), with 5/6 of the 
remaining tumours harbouring ATRX mutation. (Figure 4E). There was strong 
immunoreactivity for H3K27M in 12/12 cases tested. (Figure 4F). Two patients had distinct, 
separate lesions in the thalamus and hypothalamus, whilst the remaining had central thalamic, 
midbrain or cerebellar localization (Figure 4C). Although conferring a worse prognosis across 
the whole cohort (above), within midline locations there was no association with either EFS 
(median=7.9 months; p=0.482, log-rank test) or OS (median=14.2 months; p=0.839, log-rank 
test) (Figure 4G), nor any prognostic value for WHO grade in K27M tumours (p=0.646 EFS 
and p=0.762 OS, log-rank test) (Figure S5B). 
 
 
Immune-positive subgroups are associated with MAPK and benefit from the addition of BEV 
Paediatric HGGs with a high mutational burden had previously been described to have an 
elevated neoantigen load, and a pronounced immune response (Bouffet et al., 2016). Four 
cases were classed as hypermutator, with a median somatic mutation count of 4848 
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(range=2197-5332; mutation rate 160-240 mutation/Mb) (Figure 5A, Table S1A). Mutation 
signature analysis showed predominantly C>T transitions and hotspot somatic POLE 
mutations in three cases, and a somatic POLD1 mutation in the fourth (Figure 5B). They were 
all categorised as glioblastoma, and in one case, the presumed mismatch repair deficiency 
was demonstrated by clear loss of MLH1 expression by immunohistochemistry (Figure 5C). 
This specimen had a heterogeneous immune phenotype, with a relatively high percentage of 
CD8+ cells in the central area, and in three or four thin perivascular cuffs (Figure 5D). These 
hypermutator cases had the highest percentage of CD8+ cells (p<0.0001 t-test versus rest 
excluding PXA-like) (Figure 5E). Notably, PXA-like tumours were also significantly enriched 
for CD8+ cells (p<0.0001 t-test versus rest excluding hypermutator). Of three HGG-WT cases 
with relatively high immune infiltrate, two had elevated somatic SNV counts (100-110 per 
case), whilst the third scored highly for the “GBM_LYMPH_HI” subgroup by methylation 
profiling. A formal histological assessment of tumour infiltrating lymphocytes (TILs) confirmed 
the highest scoring categories (lymphocytes scattered amongst tumour cells / in more than 
50% of the tumour) to be almost exclusively present in hypermutator and PXA-like subgroups 
(Figure S6A), as were those cases formally classified as an inflamed immune phenotype 
(Figure S6B). Histone mutant tumours were notably immune cold as defined by a lack of CD8-
immunoreactivity and an absence of TILs.  
 
Nine cases classified by 450k methylation profiling as more similar to PXAs than high grade 
gliomas. 5/9 (55%) harboured BRAF_V600E mutations, with 3/5 (60%) also containing 
CDKN2A/B deletions and/or TERT amplification or promoter mutation (C250T) (Figure 6A). 
3/4 of the remaining cases were instead found with somatic NF1 mutation, often in concert 
with TP53 (3/4) and/or ATRX mutation (2/4). Upon histological re-review according to WHO 
2016 guidelines by the HERBY Pathology Committee, BRAF_V600E cases were all found to 
comprise the epithelioid variant of grade IV glioblastoma, whilst the NF1 cases were all 
classified as the giant cell variant (Figure 6B). PXA-like tumours had a high degree of immune 
infiltrate, with cases exhibiting several perivascular cuffs of more than three layers of CD8+ T 
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cells, which were also scattered among tumour cells in more than 50% of the specimen (Figure 
6C). They were found bilaterally restricted to temporo-parietal regions with a medial 
hemispheric predominance (Figure 6D). 
 
Gene expression data from RNA sequencing were available for a subset of samples, in which 
a CD8 T effector / T cell signature was found to correlate with CD8-positivity by 
immunohistochemistry (r2=0.49138, p=0.00523), with two hypermutator cases as outliers 
(Figure 7A).  Although no PXA-like or BRAF_V600E mutant cases were included in this 
subset, these signatures were particularly evident in cases with predicted MAPK pathway-
activating alterations in NF1 (truncating frameshift/nonsense, disrupting translocation or 
predicted damaging missense), NTRK2 (translocation or tandem duplication of kinase 
domains) and FGFR1 (known activating hotspot mutation) (Figure 7B). GSEA showed multiple 
enrichments for gene sets associated with T cell signalling and the immune response (e.g. 
PID_CD8_TCR_ DOWNSTREAM_PATHWAY, enrichment score=0.594, nominal p=0.0020; 
KEGG_T_CELL_RECEPTOR_SIGNALING_PATHWAY, enrichment score=0.532, nominal 
p=0.0297) and inflammatory-related MAPK signalling (e.g. ST_JNK_MAPK_PATHWAY, 
enrichment score=0.466, nominal p=0.0332; REACTOME_GRB2_SOS_PROVIDES_ 
LINKAGE_TO_MAPK_SIGNALING_FOR_INTERGRINS, enrichment score=0.581, nominal 
p=0.0239) (Table S2), with mean T effector / T cell signature significantly  higher than in cases 
without MAPK alterations (p=0.0039, t-test) (Figure 7C). This was validated in a restricted 
cohort of n=59 patients from our retrospective analysis designed to approximate the HERBY 
cohort (i.e. non-brainstem pHGG aged 3-18 years), in which we observed a significantly 
elevated T effector / T cell gene expression signature in MAPK-altered samples (p=0.0018, t-
test) (Figure S6C,D), further evidenced by GSEA (e.g. PID_CD8_TCR_ 
DOWNSTREAM_PATHWAY, enrichment score=0.551, nominal p=0.0099; 
BIOCARTA_TCR_PATHWAY enrichment score=0.520, nominal p=0.0305) (Table S2). 
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We also explored other immune-related gene expression signatures in the RNAseq data, and 
noted a trend towards an elevated macrophage M2 response in MAPK-altered tumours 
(p=0.0810, t-test) (Figure S6E,F). We performed CD68 staining for a limited number of cases 
with a histologically defined immune response (n=11), and found a heterogeneously 
distributed tumor-associated macrophages (TAM) component, comprising either TAM-free 
tumoral areas, or rich TAM areas especially around necrotic foci or associated with 
perivascular lymphocytes (Figure S6G). BRAF_V600E cases had CD68+ TAM more diffusely 
intermingled with tumour cells (Figure S6G). Although the presence of macrophage infiltration 
has previously been reported in diffuse intrinsic pontine glioma (Caretti et al., 2014), we 
observed no association of the M2 gene expression signature with K27M midline tumours in 
our cohort (p=0.965).   
 
With the primary efficacy analysis failing to demonstrate survival differences between the two 
arms, we explored whether the molecular profiling data could identify subsets of patients who 
may have benefited from the addition of BEV to the standard chemoradiotherapy. We 
performed a univariate Cox regression analysis on methylation-based molecular subgroup as 
well as individual gene-level alterations, and found none which had significant difference in 
outcome between investigational arms (Figure S7A), although NF1, PDGFRA and TP53 were 
adverse prognostic markers across the whole cohort (Figure S7B-E). Notably however, whilst 
not predictive in the TMZ/RT arm (Figure 7D), the presence of high levels of CD8+ T cells 
within the central tumour area conferred a significantly better overall survival in children 
receiving the addition of BEV (p=0.0404, log-rank test) (Figure 7E). Fitting a Cox interaction 
model (with proportional hazards confirmed by calculating Schoenfeld residuals, p=0.268), 
high CD8 levels trended towards predictivity of response to TMZ/RT+BEV, with hazard ratio 
of 0.360 (p=0.066). In keeping with the strong subgroup associations described, 17/18 cases 
with high levels of CD8+ T cells are hemispheric (representing 38.6% cases in this location). 
Within hemispheric tumours only, there is a significant interaction between high CD8 and BEV 
(HR=0.251, p=0.024). 
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Discussion  
The HERBY trial opened in October 2011, prior to the discovery of histone gene mutations in 
2012 (Schwartzentruber et al., 2012), and the more extensive genome sequencing published 
in 2014 (Wu et al., 2014), and there were no molecular markers incorporated into trial design. 
The present correlative biology study demonstrates the extent of the heterogeneous 
population of tumours, with widely differing biological drivers and clinicopathological features, 
which were included in the cohort. An important example is the four adolescent patients with 
IDH1 mutation, who had a significantly better clinical outcome, and may now be thought of as 
the lower age limit of an adult subgroup rather than ‘paediatric’ HGG. Such patients will likely 
be included in future IDH1-focussed trials across adult and paediatric oncology services in 
order to maximize the possibility of positive trial outcomes. Similarly, within the HERBY cohort 
were seven patients with BRAF_V600E mutations, who would now be candidates for upfront 
trials of targeted inhibitors such as vemurafenib (Bautista et al., 2014; Robinson et al., 2014), 
and four hypermutator patients, with somatic POLE/POLD1 mutations and likely harbouring 
biallelic mismatch repair deficiency syndrome, who may benefit from immune checkpoint 
inhibitors such as nivolumab (Bouffet et al., 2016). In both instances, early clinical data shows 
remarkably promising results and there would be little justification in their continued inclusion 
in catch-all HGG trials.  
 
Notably, both hypermutator cases and those biologically resembling PXAs, the latter of which 
harboured either BRAF or NF1-driven MAP-kinase alterations, were found to be the most 
immunogenic in terms of CD8+ T cells / tumour infiltrating lymphocytes, including a significantly 
elevated CD8 effector T cell gene expression signature. This is important given reports in adult 
glioblastoma of an immunosuppressive phenotype associated with an elevated CD8+ 
regulatory T cell immune infiltrate (Kmiecik et al., 2013). The MAPK-altered hypermutator and 
PXA-like paediatric cases in the present cohort were found to benefit from the addition of BEV 
to TMZ/RT in regards overall, though not event-free survival, the first and only such predictive 
biomarker identified in this patient population. The immunomodulatory effects of anti-
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angiogenic therapies have been previously demonstrated in other cancer types (Elamin et al., 
2015), with VEGF-A shown to play an important role in the induction of an immunosuppressive 
environment (Gabrilovich et al., 1996), through increasing PD-L1 and other inhibitory 
checkpoints involved in CD8+ T cell exhaustion.  
 
An important implication of these observations is the possibility of overcoming resistance to 
BRAF/MEK-targeting therapies by combining them with BEV and/or other immune therapies 
in these subgroups, as has been suggested in melanoma (Hu-Lieskovan et al., 2015). Such 
a strategy is however complicated by the diverse roles on T cell function played by MAPK 
signalling. Although involved in the regulation of T cell proliferation and survival (D'Souza et 
al., 2008), selective BRAF inhibitors have been shown to increase CD8+ lymphocytes in 
human metastatic melanoma models (Wilmott et al., 2012). Crucially, although MEK inhibition 
has been demonstrated to block naïve CD8+ T cell priming in a colon cancer model, the 
number of CD8+ effector T cells within the tumour were increased, and could potentiate 
immune checkpoint therapy (Ebert et al., 2016). A limitation of the present study is the small 
numbers in this post hoc analysis, and the benefit that patients with these biological subgroups 
may derive from an immunomodulatory mechanism of BEV would need to be tested in the 
prospective setting. This is a challenge given that these patients represent approximately 10-
15% of an already rare disease, however international collaborative trials groups (such as 
those in HERBY represent), already recruit hypermutator and MAPK-altered HGGs in this 
population for appropriately targeted therapies (NCT02992964, NCT02684058). Equally 
importantly, the histone H3 mutant subgroups which represent a substantial proportion of 
patients in this age group (Mackay et al., 2017) were found to be very poorly immunogenic, 
confirming a previous study in resectable malignant brainstem gliomas in children and adults 
with K27M mutations (Zhang et al., 2017), and further negating the likelihood of clinical 
response to such therapies. 
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A key observation is the high prevalence of tumours occurring outside the cerebral 
hemispheres harbouring histone mutations, included in the most recent 2016 WHO 
classification system as a novel entity called diffuse midline glioma with H3K27M mutation. 
These represented 27% of the assessed population, and had a particularly poor outcome, as 
did histone wild-type midline cases. These tumours only rarely have MGMT promoter 
methylation, and have consistently proved refractory to TMZ and other chemotherapeutic 
agents (Jones et al., 2016). Critically, midline K27M tumours classified histologically as either 
grade 3 or 4 according to the WHO2007 classification had no difference in clinical outcome 
within the HERBY cohort, and with the caveat of small numbers, support the current 2016 
guidelines to assign all such tumours as grade 4 on the basis of their location and molecular 
findings.  
 
More surprising was the poor outcome observed for patients with H3F3A_G34R/V mutations. 
A previous study reported G34R mutations to convey a better prognosis in respect of overall 
survival (HR 0.49, p=0.01), though this was not significant in multivariate analysis (p=0.84) 
(Korshunov et al., 2015), although the present study is the first study to explore this in a 
consistently treated and well-annotated clinical trial setting. In the HERBY study as well in 
published work (Korshunov et al., 2015; Mackay et al., 2017), H3F3A_G34R/V mutation is 
associated with a high frequency of MGMT methylation. Notably, MGMT promoter methylation 
itself was not predictive in this trial cohort of all patients receiving radiochemotherapy with 
temozolomide, again demonstrating differences with the adult disease, and questioning the 
continued use of protocols extrapolated from the adult setting. It is clear that histone mutations 
represent clearly-defined entities within an umbrella HGG classification in the paediatric 
setting, and given their profound impact on chromatin modifications, will require novel 
therapeutic development and clinical trials distinct from histone wild-type cases.  
 
Within the remaining cases of paediatric HGG were a small proportion whose methylation 
profiles were more similar to other lesions. The LGG-like cases were in young patients with 
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longer EFS, whilst two additional cases had methylation classifier scores strongly suggestive 
of newly-described entities coming from the study of tumours formally diagnosed as CNS 
primitive neuroectodermal tumours (CNS-PNET) (Sturm et al., 2016). Integration with 
histological features and determination of the presence of marker gene fusions events for 
these entities (CNS HGNET-MN1, CNS NB-FOXR2) will be key in future studies. 
 
Although there have been several early phase and anecdotal studies of BEV in paediatric 
HGG (Benesch et al., 2008; Friedman et al., 2013; Gururangan et al., 2010; Narayana et al., 
2010; Salloum et al., 2015), none have included biological information on the patients treated. 
Aside from CD8 immunoreactivity, we did not identify any additional molecular markers of 
response. In similarly-designed adult studies of BEV, gene expression-defined proneural 
(Sandmann et al., 2015) or mesenchymal (Sulman et al., 2013) subgroups of GBM have been 
reported to confer a significant OS advantage. Although we have not undertaken gene 
expression studies across our cohort, adult and paediatric cases expressing proneural genes 
appear to have distinct genetic and epigenetic drivers (Sturm et al., 2012), the mesenchymal 
subclass is rare in children (Sturm et al., 2012), and unlike the adult studies, we observed no 
EFS advantage of BEV in HERBY (Grill et al., 2018). 
 
In conclusion, integrated molecular profiling of the HERBY sample cohort has demonstrated 
the biological and clinicopathological diversity of the term HGG in the paediatric setting, 
suspected but not confirmed at the onset of the trial. Whilst there are several distinct 
subgroups for which there is strong rationale for bespoke future clinical studies, a large 
proportion of paediatric HGG cases continue to defy improvements in survival and lack a clear 
path forward. Although BEV was not associated with better outcome in this trial, the extensive 
biological, pathological and radiological ancillary research programmes ongoing within 
HERBY aim to provide an integrated assessment of disease pathogenesis and treatment 
response.  
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Legends for Figures 
 
Figure 1 – Sample cohort. (A) Flow diagram indicating total HERBY trial cohort (n=121 
randomised plus 3 infants), those patients consenting to the biology study (n=113) for whom 
sufficient FFPE or frozen tumour was available (n=89), and the respective molecular analyses 
undertaken. Kaplan-Meier plots of event-free survival of cases (y axis) separated by (B) 
treatment arm, (C) anatomical location, or (D) H3F3A status, with time given in months (x axis) 
and p value calculated by the log-rank test. See also Table S1. 
 
 
Figure 2 - Methylation-based subclassification. (A) Heatmap representation of beta values for 
74 samples profiled on the Illumina 450k BeadArray platform (red, high; blue, low). Samples 
are arranged in columns clustered by probes with the largest median absolute deviation 
across the 10k predictor subset of probes. Clinicopathological and molecular annotations are 
provided as bars according to the included key. CR/PR = complete response or partial 
response; Stable/NC = stable disease or no change. (B) Boxplot showing age at diagnosis of 
included cases, separated by methylation subclass. Kaplan-Meier plot of (C) event-free and 
overall survival of cases (y axis) separated by methylation subclass, time given in months (x 
axis) and overall p value calculated by the log-rank test. See also Figures S1, S2, S3 and 
Table S1. 
 
Figure 3 – Somatic mutations. (A) Oncoprint representation of an integrated annotation of 
somatic mutations and DNA copy number changes for the 30 most frequently altered genes 
in 86 samples (n3, frequency barplot on the right, excluding hypermutator cases). Selected 
common fusion events are also shown where available. Samples are arranged in columns 
with genes labelled along rows. (B) Barplots are provided on a log10 scale for numbers of copy 
number aberrations and somatic mutations per case. Clinicopathological and molecular 
annotations are provided as bars according to the included key. CR/PR = complete response 
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or partial response; Stable/NC = stable disease or no change. See also Figure S4 and Table 
S1. 
 
Figure 4 – H3F3A mutant subgroups. (A) Integrated annotation of somatic mutations and DNA 
copy number changes in 7 H3F3A_G34R/V cases. (B) H&E (top) and immunohistochemistry 
(bottom) directed against H3.3G34R. (C) Radiological tumour lesion map of H3F3A_G34R/V 
and H3F3A_K27M cases. Brighter coloured pixels indicate a higher probability of tumour 
incidence. (D) Kaplan-Meier plot of event-free and overall survival of hemispheric cases (y 
axis) separated by H3F3A status, time given in months (x axis), p value calculated by the log-
rank test. (E) Integrated data from 21 H3F3A_K27M cases. (F) H&E (top) and 
immunohistochemistry (bottom) directed against H3.3K27M. (G) Kaplan-Meier plot of event-
free and overall survival of midline cases (y axis) separated by H3F3A status, time given in 
months (x axis), p value calculated by the log-rank test. See also Figure S5 and Table S1. 
 
Figure 5 – Hypermutator cases. (A) Circos plots for four hypermutator cases. In each case, 
plots provide somatic SNVs and InDels on the outer ring, DNA copy number changes (dark 
red, amplification; red, gain; dark blue, deletion; blue, loss) and loss of heterozygosity (yellow) 
on the inner rings, and intra- (orange) and inter- (blue) chromosomal translocations inside the 
circle. (B) Mutation signatures. (Top) Simple stacked barplot representation of the proportion 
of mutation types observed in individual hypermutator cases and the remaining accumulated 
dataset. Base changes given in the key. (Bottom) Mutation context given for each of the 96 
mutated trinucleotides, represented by heatmap. The base located 5′ to each mutated base is 
shown on the vertical axis, and the 3′ base is on the horizontal axis. (C) (Top) H&E and 
(bottom) protein expression of mismatch repair proteins MLH1, MSH2, MSH6 and PMS2 as 
assessed by immunohistochemistry in a glioblastoma with 5322 somatic mutations 
(HERBY102). (D) CD8 expression in T cells by immunohistochemistry in HERBY102 (E) 
Boxplot of percentage of CD8+ cells in the central tumour region separated by subgroup.  *** 
p<0.0001, t-test. See also Table S1. 
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Figure 6 – PXA-like tumours.  (A) Integrated annotation of somatic mutations and DNA copy 
number changes in 9 samples classifying as PXA-like. (B) Haematoxylin and eosin staining of 
an epithelioid (top) and giant cell (bottom) variant of glioblastoma. (C) CD8 
immunohistochemistry for the same cases as (B), marking CD8+ T cells. (D) Radiological 
tumour lesion map of PXA-like cases. Brighter coloured pixels indicate a higher probability of 
tumour incidence. See also Table S1. 
 
Figure 7 – Immune signatures and response to bevacizumab. (A) Mean T effector / T cell 
gene expression values (plotted as log2, x axis) data were correlated with CD8 
immunoreactivity (plotted as log10, y axis). Two cases were scored as 0% by IHC and were 
not plotted (expression values -7.37 and -7.58). (B) Gene expression signatures for CD8 T 
effector and T cells plotted as a heatmap from RNAseq data. Hypermutator cases and those 
with MAPK alterations including NF1, FGFR1 or NTRK2 are annotated.  (C) Boxplot of T 
effector / T cell gene expression values in MAPK altered samples compared to those without. 
Bold line represents the median, whiskers span the interquartile range. (D) Kaplan-Meier plot 
of event-free and overall survival of cases (y axis) treated with TMZ/RT, separated by levels 
of CD8+ T cells, time given in months (x axis) and p value calculated by the log-rank test. (E) 
TMZ/RT plus BEV, separated by levels of CD8+ T cells, time given in months (x axis) and p 
value calculated by the log-rank test. See also Figures S6-S7 and Table S1. 
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STAR Methods  
CONTACT FOR REAGENT AND RESOURCE SHARING  
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Chris Jones (chris.jones@icr.ac.uk).  
 
EXPERIMENTAL MODEL AND SUBJECT DETAILS  
Patient samples 
All patient samples were collected after signed consent to the HERBY translational research 
program, under full Research Ethics Committee approval at each participating centre. Tumour 
material was available from 89 patients (out of a total of 113 providing consent) from 13 
countries (France n=27, UK n=17, Italy n=14, Spain n=6, Canada n=5, Netherlands n=4, 
Czech Republic n=3, Denmark n=3, Hungary n=3, Sweden n=3, Poland n=2, Austria n=1, 
Belgium n=1).   
 
Pathological review 
All patients had their initial local diagnosis of HGG confirmed according to the WHO 2007 
classification by a central HERBY reference neuropathologist prior to enrollment. 
Subsequently, all specimens were further subjected to a consensus review by the HERBY 
panel of five independent expert paediatric neuropathologists, who also applied the diagnostic 
criteria of the WHO 2016 classification.  
 
Radiological anatomical localization 
Tumour localization was determined by the HERBY panel of paediatric neuroradiologists. 
Tumours were assigned to lobar, basal ganglia, thalamic, non-pontine brainstem or cerebellar 
locations. As many of the tumours spanned more than one of these locations, post hoc 
radiological analysis by one of the HERBY Neuroradiologists was undertaken to determine 
  29 
the epicentre of the tumour origin; this was used to classify the site of origin of the tumour in 
each case. 
 
METHOD DETAILS  
Nucleic acid extraction 
DNA was extracted from frozen tissue by homogenisation prior to following the DNeasy Blood 
& Tissue kit protocol (Qiagen, Crawley, UK). DNA was extracted from formalin-fixed, paraffin-
embedded (FFPE) pathology blocks after manual macrodissection using the QIAamp DNA 
FFPE tissue kit protocol (Qiagen). Matched normal DNA was extracted from blood samples 
using the DNeasy Blood & Tissue kit (Qiagen, Crawley, UK). Concentrations were measured 
using a Qubit fluorometer (Life Technologies, Paisley, UK). RNA was extracted by following 
the RNeasy Mini Kit protocol (Qiagen), and quantified on a 2100 Bioanalyzer (Agilent 
Technologies). 
 
H3F3A Sanger sequencing 
PCR for H3F3A was carried out on 89 cases using primers obtained from Life Technologies 
(Paisley, UK) (FFPE: for-TGGCTCGTACAAAGCAGACT; rev-
ATATGGATACATACAAGAGAGACT; FROZEN: for-GATTTTGGGTAGACGTAATCTTCA; 
rev-TTTCCTGTTATCCATCTTTTTGTT). Sequences were analysed using Mutation Surveyor 
(SoftGenetics, PN, USA) and manually with 4Peaks (Nucleobytes, Aalsmeer, Netherlands). 
Only three cases left insufficient DNA for exome sequencing, all of which were found to 
harbour K27M mutations, and thus additional Sanger sequencing for genes encoding H3.1 
variants were not undertaken. 
 
Methylation profiling 
50-500ng DNA was bisulphite-modified and analyzed for genome-wide methylation patterns 
using the Illumina HumanMethylation450 BeadArray (450k) platform at either the DKFZ or the 
University College London Genomics Centre, according the manufacturers instructions. All 
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samples were checked for expected and unexpected genotype matches by pairwise 
correlation of the 65 genotyping probes on the 450k array. 
 
MGMT promoter methylation 
To evaluate the methylation status of the MGMT promoter region, we used either the MGMT_STP27 
logistic regression model from Illumina 450k methylation array data, or methylation-specific (MS-) 
PCR. For MS-PCR, 300-1500ng DNA was sodium bisulphite-treated and PCR products analyzed 
on an the ABI7900HT instrument (Applied Biosystems, Foster City, CA, USA) to quantify the copy 
number of MGMT/ACTB (MDxHealth, Irvine, CA, USA).  
 
Next-generation sequencing 
50-500ng DNA from 86 cases was sent for exome sequencing at the Tumour Profiling Unit 
(ICR, London, UK) using the Agilent SureSelectXT Human All Exon V6 platform with additional 
customized coverage of all histone H3 genes and the TERT promoter (Agilent, Santa Clara, 
CA, USA), and paired-end-sequenced on an Illumina HiSeq2500 (Illumina, San Diego, CA, 
USA) with one single patient-matched tumour/normal pair per lane where possible. The 
average median coverage was 426x for the frozen tumours (range 351-598x), 321x for the 
FFPE tumours (range 115-519x) and 163x for normal samples (range 116-464x). A 
customized panel of biotinylated DNA probes (NimbleGen) was developed for the detection 
of structural variants (translocations and duplications) and potential amplifications. The panel 
capture a total of 22 genes recently implicated in brain tumours (ALK, BCOR, BRAF, c11orf95, 
C19MC, CIC, ETV6, FGFR1-3, FOXR2, KIAA1549, MET, MN1, MYB, MYBL1, NTRK1-3, 
RAF, RELA, TPM3 and YAP1). Library preparation was performed using 50-200 ng of 
genomic DNA using the HyperPlus Kit (Kapa Biosystems, Wilmington MA, USA) and SeqCap 
EZ adapters (Roche). Following fragmentation, DNA was end-repaired, A-tailed and indexed 
adapters ligated. DNA was amplified, multiplexed and hybridized using 1 µg of total pre-
capture library DNA to the design of DNA baits (NimbleGen SeqCap EZ Developer library, 
Roche). After hybridization, capture libraries were amplified and sequencing was performed 
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on a NextSeq500 (Illumina) with 2 x 150bp, paired-end reads following manufacturer’s 
instructions. RNA from frozen tumours was sequenced on an Illumina HiSeq2500 as 100bp 
paired end reads. 
 
Immunohistochemistry  
4µM sections were stained by an automated Discovery XT (for H3G34R) or Benchmark XT 
(Ventana Medical Systems, Tucson, USA). A standard pre-treatment protocol included CC1 
buffer (or CC2 for H3G34R) and then a primary antibody incubation for 32 minutes (92 minutes 
for MLH1, PMS2, MSH2 and MSH6) at room temperature (37C for H3K27M and MLH1). 
Antibodies used were directed against MLH1 (BD Pharmingen, clone G168-728, 
1/300),  PMS2 (BD Pharmingen, clone A16-4, 1/150), MSH2 (DIAG-BIOSYSTEMS, clone 
25D12, 1/10), MSH6 (DIAG-BIOSYSTEMS, clone 44, 1/50), H3K27M (Merck, polyclonal, 
1/1000), CD8 (Dako, clone C8/144B, 1/100), CD68 (Glostrup, clone KP1, 1/400) and H3G34R 
(kind gift from Richard Grundy, Children’s Brain Tumor Research Centre,  Nottingham, UK, 
polyclonal; 1/150). Antibody binding was visualized with an Optiview Kit (Roche-Ventana, 
Tucson, USA). Diaminobenzidine-tetra-hydrochloride (DAB, Ventana) was used as the 
chromogen.  
 
Pathological assessment of immune response 
CD8 immunoreactivity was assessed as the percentage of the surface area of the tumour 
covered by CD8+ cells present at a density belonging to one of four reference bins of 
increasing density (I0, I1, I2, I3). A further quantitative assessment of the percentage of the 
pathologist-defined central tumour area of CD8+ cells was also performed. A qualitative 
categorization of the tumour as a whole as either ‘inflamed’, ‘heterogeneous’ or an immune 
‘desert’ was also provided. Patients in the upper quartile of central tumour area CD8 cell 
positivity with a heterogeneous or inflamed phenotype were classed as CD8-high. A 
histologically-defined assessment of tumour infiltrating lymphocytes (TILs) was carried out 
according to two distinct schema. Palma et al. (Palma et al., 1978) includes Category A 
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(several perivascular cuffs of more than three layers of lymphocytes and often lymphocytes 
also scattered among tumor cells), Category B (three or four thin perivascular cuffs in the 
tumor) and Category C (no clear lymphocytes present); Rutledge et al. (Rutledge et al., 2013) 
includes Category 0 (absence of lymphocytes), Category 1+ (lymphocytes in less than 50% 
of the tumor) and Category 2+ (lymphocytes in more than 50% of the tumor). 
 
QUANTIFICATION AND STATISTICAL ANALYSIS  
Sequence analysis 
Exome capture reads were aligned to the hg19 build of the human genome using bwa v0.7.5a 
(bio-bwa.sourceforge.net), and PCR duplicates removed with PicardTools 1.5 
(pcard.sourceforge.net). Somatic single nucleotide variants were called using the Genome 
Analysis Tool Kit v3.3-0 based upon current Best Practices using local re-alignment around 
InDels, downsampling and base recalibration with variants called by the Unified Genotyper 
(broadinstitute.org/gatk/). Somatic variants were covered by at least 20 reads in both tumour 
and normal sequences and carried at least 5 ALT reads in the tumour sequence; unmatched 
exomes (n=3) were annotated by ExAc and ANNOVAR. Variants were annotated using the 
Ensembl Variant Effect Predictor v74 (ensembl.org/info/docs/variation/vep) incorporating 
SIFT (sift.jcvi.org) and PolyPhen (genetics.bwh.harvard.edu/pph2) predictions, COSMIC v64 
(sanger.ac.uk/ genetics/CGP/cosmic/) and dbSNP build 137 (ncbi.nlm.nih.gov/sites/SNP) 
annotations. Copy number was obtained by calculating log2 ratios of tumour/normal coverage 
binned into exons of known Ensembl genes, smoothed using circular binary segmentation 
(DNAcopy, www.bioconductor.org) and processed using in-house scripts. Mutation signatures 
were ascertained by grouping somatic substitutions on the basis of their 3′ and 5′ bases into 
96 possible trinucleotide categories (Shlien et al., 2015). NGS fusion panel alignment was 
performed against the human reference sequence GRCh37/Hg19. Quality control (QC), 
variant annotation, deduplication and metrics were generated for each sample. Manta 
(https://github.com/Illumina/manta) and Breakdancer (breakdancer.sourceforge.net) were 
used for the detection of structural variants. 
  33 
 
Methylation profiling 
Methylation data from the Illumina Infinium HumanMethylation450 BeadChip was preprocessed 
using the minfi package in R. DNA copy number was recovered from combined intensities using 
the conumee package with reference to methylation profiles from normal individuals provided in the 
CopyNumber450kData package. We have used the Heidelberg brain tumour classifier(Capper et 
al., 2018) (molecularneuropathology.org) to assign subgroup scores for each tumour compared to 
91 different brain tumour entities using a training set built from 2801 tumours implemented in the 
MNP R package (v11b2). Simplified methylation subgroup assignments were then made to 
incorporate cases carrying G34R/V or K27M mutations in H3 histones, IDH1 mutation at R132, low 
grade glioma-like profiles (predominantly diffuse infantile ganglioglioma and pilocytic astrocytoma) 
and those similar to pleomorphic xanthoastrocytoma (PXA). Low-scoring cases, or those with a high 
normal cell contamination were assigned to G34, K27 or IDH1 groups if the respective mutation was 
identified. Wild-type HGG encompassed many other methylation subgroups and were simply 
assigned by exclusion with the groups above. Clustering of beta values from methylation arrays was 
performed using the 10K probeset from the Heidelberg classifier based upon Euclidean distance 
with a ward algorithm. Methylation heatmaps show only the most variable probes of the classifier 
between simplified methylation subgroups. 
 
RNAseq 
RNA sequences were aligned to hg19 and organised into de-novo spliced alignments using 
bowtie2 and TopHat version 2.1.0 (ccb.jhu.edu/software/tophat). Fusion transcripts were 
detected using chimerascan version 0.4.5a filtered to remove common false positives. 
RNASeq raw count files were used to construct an expression matrix using Roche's internal 
pipeline. The expression matrix was normalized using edgeR and Voom in R 
(cran.rproject.org/), and a heatmap was created from the absolute gene expression data using 
Tibco Spotfire, as previously described (Brouwer-Visser et al., 2018). The mean expression 
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of the signature genes was used to compare MAPK-altered to non-altered samples and 
statistical significance calculated using a two-tailed unpaired t-test. The mean expression was 
also used to correlate with CD8 positivity by IHC. Gene Set enrichment analysis was 
performed using the GSEA java application based upon pairwise comparisons of MAPK 
altered versus wild-type for curated canonical gene sets.  All data are deposited in the 
European Genome-phenome Archive (ebi.ac.uk/ega/home) under accession number 
EGAS00001002328. 
 
Tumour lesion maps 
Pre-surgery tumour volume regions of interest (ROIs) were drawn on T2-weighted/Fluid-
attenuated inversion recovery (FLAIR) magnetic resonance (MR) images by an experienced 
paediatric neuroradiologist (TJ). The images and corresponding ROIs were affinely registered, 
using FSL (Jenkinson et al., 2002), to a paediatric template (Left-Right Symmetric, 7.5–13.5 
years old) from the Montreal Neurological Institute 
(http://www.bic.mni.mcgill.ca/ServicesAtlases/NIHPD-obj1) (Fonov et al., 2011).  A further 
manual correction step was performed to limit tumour mass effects. Once registered to a 
common space, overall tumour lesion overlap maps were created using MRIcron (Rorden et 
al., 2007).  
 
Statistical analysis 
Statistical analysis was carried out using R 3.3.0 (www.r-project.org) and GraphPad Prism 7. 
Categorical comparisons of counts were carried out using Fishers exact test, comparisons 
between groups of continuous variables employed Student’s t-test or ANOVA. Univariate 
differences in survival were analysed by the Kaplan-Meier method and significance 
determined by the log-rank test. Exploratory Cox regression analyses were conducted to 
assess the impact of molecular prognostic and predictive factors. Confirmation of proportional 
hazards was assessed by calculating Schoenfeld residuals. All tests were two-sided and a p 
value of less than 0.05 was considered significant. 
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DATA AND SOFTWARE AVAILABILITY  
All newly generated data have been deposited in the European Genome-phenome Archive 
(www.ebi.ac.uk/ega) with accession number EGAS00001002328 (sequencing) or 
ArrayExpress (www.ebi.ac.uk/arrayexpress/) with accession number E-MTAB-5552 (450k 
methylation).  
 
ADDITIONAL RESOURCES  
Curated gene-level copy number, mutation data and RNAseq data are provided as part of the 
paediatric-specific implementation of the cBioPortal genomic data visualization portal 
(pedcbioportal.org). Raw data files are also made available through the Cavatica NIH-
integrated cloud platform (cavatica.org). 
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Supplemental Tables 
 
Table S1 (related to Figures 1-7) – Summary of clinicopathological and molecular data. (A) 
Sample cohort. (B) Methylation-based subclassification. (C) Focal amplifications and 
deletions. (D) Chromosomal gains and losses. (E) Somatic single nucleotide variants and 
small insertions/deletions. (F) Candidate gene fusions.  
 
Table S2 (related to Figure 7) – Gene set enrichment analysis of MAPK altered versus wild-
type paediatric high grade glioma in the HERBY and meta-analysis datasets. Provided are the 
names of curated canonical datasets, the enrichment score (ES), normalised enrichment 
score (NES), the nominal (NOM) p value, the false discovery rate (FDR) q value, the family-
wise error rate (FWER) p value and the position in the ranked list at which the maximum 
enrichment score occurred (RANK AT MAX).  
 
 
 
 
 
 
 
 
 
 KEY RESOURCES TABLE 
REAGENT or RESOURCE SOURCE IDENTIFIER 
Critical Commercial Assays 
DNeasy blood & tissue kit Qiagen 69504 
QIAmp DNA FFPE tissue kit Qiagen 56404 
RNeasy mini kit Qiagen 74104 
QIAquick PCR purification kit Qiagen 28104 
BigDye terminator v3.1 mix Thermo Fisher 4337455 
SureSelect Human All Exon capture set V6 Agilent 5190-8863 
SureSelect RNA Capture, 0.5-2.9Mb Agilent 5190-4944 
 
Deposited Data 
Exome and RNA sequencing of new samples This paper EGA: 
EGAS00001002328 
Illumina methylation BeadChip profiling of new samples This paper ArrayExpress:  
E-MTAB-5552 
Sequencing and methylation data This paper cavatica.org 
 
Oligonucleotides 
Primer: H3F3A_forward FFPE 
TGGCTCGTACAAAGCAGACT 
This paper N/A 
Primer: H3F3A_reverse FFPE 
ATATGGATACATACAAGAGAGACT 
This paper N/A 
Primer: H3F3A _forward FROZEN 
GATTTTGGGTAGACGTAATCTTCA 
This paper N/A 
Primer: H3F3A _ reverse FROZEN 
TTTCCTGTTATCCATCTTTTTGTT 
This paper N/A 
 
Antibodies 
MLH1 BD Pharmingen G168-728 
PMS2 BD Pharmingen A16-4 
MSH2 DIAG-BIOSYSTEMS 25D12 
MSH6 DIAG-BIOSYSTEMS 44 
H3K27M Merck ABE419 
H3G34R University of 
Nottingham 
richard.grundy@notti
ngham.ac.uk 
CD8 Dako C8/144B 
CD68 Glostrup KP1 
 
Software and Algorithms 
Mutation Surveyor SoftGenetics softgenetics.com/mu
tationSurveyor.php 
4Peaks Nucleobytes nucleobytes.com/4p
eaks/ 
minfi BioConductor bioconductor.org/pac
kages/release/bioc/h
tml/minfi.html 
conumee BioConductor bioconductor.org/pac
kages/release/bioc/h
tml/conumee.html 
BEDtools University of Utah github.com/arq5x/be
dtools2 
Key Resource Table
 DNAcopy BioConductor bioconductor.org/pac
kages/release/bioc/h
tml/DNAcopy.html 
CopyNumber450kData BioConductor bioconductor.org/pac
kages/release/data/e
xperiment/html/Copy
Number450kData.ht
ml 
MNP DKFZ Heidelberg molecularneuropath
ology.org/mnp 
Bowtie2 Johns Hopkins 
University 
bowtie-
bio.sourceforge.net/
bowtie2/index.shtml 
TopHat Johns Hopkins 
University 
ccb.jhu.edu/software
/tophat/index.shtml 
cufflinks University of 
Washington 
ole-trapnell-
lab.github.io/cufflinks
/cufflinks/ 
DESeq2 BioConductor bioconductor.org/pac
kages/release/bioc/h
tml/DESeq2.html 
Gene Set Enrichment Analysis Broad Institute http://software.broadi
nstitute.org/gsea 
bwa Sanger Institute http://bio-
bwa.sourceforge.net/ 
Genome Analysis Toolkit Broad Institute oftware.broadinstitut
e.org/gatk/ 
Variant Effect predictor Ensembl tools ensembl.org/info/doc
s/variation/vep 
BCBio Harvard TH Chan bcb.io/ 
ANNOVAR Children’s Hospital of 
Philadelphia 
annovar.openbioinfo
rmatics.org/en/latest/ 
ExAc Broad Institute exac.broadinstitute.o
rg/ 
SIFT J Craig Venter 
Institute 
sift.jcvi.org 
PolyPhen Harvard genetics.bwh.harvar
d.edu/pph2 
Manta Illumina github.com/Illumina/
manta 
Breakdancer Washington University 
of St Louis 
breakdancer.sourcef
orge.net 
Oncoprinter Memorial Sloan 
Kettering 
cbioportal.org/oncop
rinter.jsp 
Circos Michael Smith 
Genome Sciences 
Center 
circos.ca 
R The Comprehensive R 
Archive Network 
r-project.org 
 
Other 
Integrated mutation, copy number, expression and 
methylation data 
This paper and cited 
sources 
pedcbioportal.org 
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Figure S1 (related to Figure 2) – MGMT promoter methylation. (A) Barplots of number of 
cases with methylated MGMT promoter, subdivided by methylation subgroup. (B) Kaplan-
Meier plot of event-free and overall survival of cases (y axis) separated by MGMT status, time 
given in months (x axis) and p value calculated by the log-rank test. (C) Heatmap 
representation of segmented DNA copy number for 86 samples derived from exome coverage 
data (dark red, amplification; red, gain; dark blue, deletion; blue, loss). Samples are arranged 
in columns clustered by gene-level data across the whole genome. Clinicopathological and 
molecular annotations are provided as bars according to the included key. CR/PR = complete 
response or partial response; Stable/NC = stable disease or no change. 
 
  
Figure S2 (related to Figure 2) – Alternate brain tumour entity and LGG-like cases. (A) 
Haematoxylin and eosin staining of the case most closely resembling CNS HGNET-MN1, as 
demonstrated by a (B) boxplot of reference methylation classifier scores, and (C) the presence 
of a novel MN1:CARD6 gene fusion by capture panel sequencing. (D) Integrated annotation 
of somatic mutations and DNA copy number changes in 9 samples classifying as LGG-like. 
(E) Haematoxylin and eosin staining of the three cases, all histologically classified as 
glioblastoma – (left) the presence of both low- and high grade areas of the tumour harbouring 
BRAF_V600E mutation; (top right) case harbouring an intragenic FGFR1 duplication (both 
previous cases classifying as pilocytic astrocytoma); (bottom left) a cased from the infant 
cohort, with a methylation profile most closely resembling desmoplastic infantile 
ganglioglioma. (F) Radiological tumour lesion map of LGG-like cases. Brighter coloured pixels 
indicate a higher probability of tumour incidence. 
 
  
 
Figure S3 (related to Figure 2) – IDH1 mutant tumours.  (A) Integrated annotation of somatic 
mutations and DNA copy number changes in 4 samples with IDH1_R132 mutation. (B) 
Haematoxylin and eosin staining of cases showing astrocytic (top) and oligodendroglial 
(bottom) histological features. (C) Kaplan-Meier plot of event-free and overall survival of cases 
(y axis) separated by IDH1_R132 status, time given in months (x axis) and p value calculated 
by the log-rank test. (D) Radiological tumour lesion map of IDH1 cases. Brighter coloured 
pixels indicate a higher probability of tumour incidence. 
 

Figure S4 (related to Figure 3) – Somatic mutations. (A) Oncoprint representation of an 
integrated annotation of somatic mutations and DNA copy number changes for the 30 most 
frequently altered genes in 86 samples (n³3, frequency barplot on the right, excluding 
hypermutator cases), ordered by histone and methylation subgroups. Selected common 
fusion events are also shown where available. Samples are arranged in columns with genes 
labelled along rows. Barplots are provided on a log10 scale for numbers of copy number 
aberrations and somatic mutations per case. Clinicopathological and molecular annotations 
are provided as bars according to the included key. CR/PR = complete response or partial 
response; Stable/NC = stable disease or no change. The annotated box highlights ‘HGG-WT’ 
tumours not otherwise assigned to a subgroup. (B) Radiological tumour lesion map of HGG-
WT cases. Brighter coloured pixels indicate a higher probability of tumour incidence. 
 
  
 
Figure S5 (related to Figure 4) – H3F3A mutant subgroups.  (A) Kaplan-Meier plot of event-
free and overall survival (y axis) of cerebral hemispheric cases, excluding those classified by 
methylation profiling as IDH1, PXA-like or LGG-like, separated by H3F3A status. Time is given 
in months (x axis) and p value calculated by the log-rank test. (B) Kaplan-Meier plot of event-
free and overall survival (y axis) of midline H3F3A_K27M cases, separated by WHO grade. 
Time is given in months (x axis) and p value calculated by the log-rank test. 
 

Figure S6 (related to Figure 7) – Immune profiling. (A) Barplot showing relative proportions of 
tumour-infiltrating lymphocytes categorised according to two schema (Palma and Rutledge), 
split by pHGG subgroups (B) Barplot showing relative proportions of histologically defined 
immune phenotype, split by pHGG subgroups. (C) Gene expression signatures for CD8 T 
effector and T cells plotted as a heatmap from combined gene expression data of non-
brainstem high-grade glioma in n=58 patients aged 3-18 years from Mackay et al., 2017. 
Hypermutator cases and those with MAPK alterations are annotated.  (D) Boxplot of T effector 
/ T cell gene expression values in MAPK altered samples compared to those without. Bold line 
represents the median, whiskers span the interquartile range. (E) Gene expression signatures 
for M2 macrophages plotted as a heatmap from RNAseq data. Hypermutator cases and those 
with MAPK alterations are annotated. (F) Boxplot of M2 macrophage cell gene expression 
values in MAPK altered samples compared to those without. Bold line represents the median, 
whiskers span the interquartile range. (G) Immunohistochemistry directed against CD68, 
showing positive cells in perivascular areas associated with lymphocytes (top, HERBY104, 
hypermutator) and more diffusely mixed with tumour cells (bottom, HERBY102, 
BRAF_V600E). 
 

Figure S7 (related to Figure 7) – Exploratory biomarker analysis. (A) Hazard ratio plot for a 
univariate Cox regression analysis on a variety of molecular subgroups and alterations in 
respect of event-free survival. Log2 hazard ratios less than zero indicate a better response to 
TMZ/RT plus BEV, ratios greater than zero a better response to TMZ/RT alone. Median (box) 
and 95% confidence intervals (whiskers) are plotted, with size of box proportion to sample 
size on an indicated category of tumours. Kaplan-Meier plot of event-free and overall survival 
of cases (y axis) separated by (B) BRAF V600E, (C) NF1, (D) PDGFRA and (E) TP53 status, 
time given in months (x axis) and p value calculated by the log-rank test.  
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